Sangamo Therapeutics(SGMO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS • Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to$1.9 billion in milestone payments, plus tiered royalties on net sales. • Reported Pfizer's announcement of positive topline r ...